What are the common side effects that Donanemab may cause?

Donanemab (Donanemab) is an innovative monoclonal antibody drug for Alzheimer's disease (AD). It mainly slows down the progression of the disease by targeting and clearing amyloid plaques in the brain. As a new disease-modifying therapeutic drug, donenemab has shown positive efficacy in clinical studies, but it is also accompanied by a certain risk of side effects. Understanding the common side effects of donenezumab is of great significance to patients and their families, as well as clinical medical staff, as it will help to identify adverse reactions in a timely manner and take effective countermeasures.

First, one of the most common side effects of donenezumab is "cerebral amyloid-related imaging abnormalities" (ARIA) associated with cerebral edema and cerebral hemorrhage. ARIAincludes two main types: ARIA-E (brain edema or abnormal signal in the brain's white matter) and ARIA-H (cerebral microbleeds or microbleeds on the brain surface). In clinical trials, a subset of patients treated with donelenumab developed these imaging abnormalities, and although most patients had mild or asymptomatic symptoms, a minority of patients may experience symptoms such as headache, confusion, nausea, vomiting, or seizures. For these patients, doctors usually monitor them regularly through magnetic resonance imaging (MRI) and adjust or suspend medication if necessary.

Secondly, injection site reactions are also a common side effect of donenemab. Patients may experience local discomfort such as redness, swelling, pain, itching, or induration at the injection site. These symptoms are generally mild and short-lasting. Correct injection technique and reasonable selection of injection sites can effectively reduce such reactions. In addition, some patients may experience allergic reactions, such as rash, fever or general itching. In rare cases, severe allergic reactions (such as anaphylactic shock) may occur, so patients should be closely observed for allergic reactions during use.

Third, donenemab may cause some non-specific systemic side effects, including headache, fatigue, fever and myalgia. These symptoms are common with many types of immunotherapy, are usually mild to moderate, and may gradually lessen as treatment is continued or the dose is adjusted. When patients experience the above symptoms, they should communicate with their doctor in a timely manner to ensure appropriate symptomatic treatment and avoid discontinuing the medication on their own.

Finally, immune system-related side effects are also an area of concern. Since donexumab is an immunomodulatory drug, it may affect the patient's immune function and increase the risk of infection, especially the incidence of respiratory tract infection and urinary tract infection. Although the incidence of such serious infections in clinical trials is relatively low, increased surveillance and preventive measures are still needed for elderly patients with weakened immune systems. In addition, long-term use of donenemab may have a certain impact on immune tolerance, which requires further clinical observation and research support.

In summary, although donenezumab, as an innovative drug for the treatment of Alzheimer's disease, has significant therapeutic potential, it is also accompanied by risks of multiple side effects such as brain amyloid-related imaging abnormalities, injection site reactions, non-specific systemic symptoms, and immune-related infections. During treatment, patients should undergo regular clinical and imaging monitoring under the guidance of professional physicians to identify and deal with adverse reactions in a timely manner. Medical staff need to strengthen the publicity and management of side effects to ensure the safety and efficacy of medication for patients and maximize the therapeutic advantages of donenemab.

Reference materials:https://www.drugs.com/donanemab.html